Interestingly, the effects of the systemically administered PACE4 inhibitory peptides on tumor progression closely replicate the phenotype observed with the PACE4 knockdown in LNCaP and DU145 cells previously described [17]. The gene discussed is PCSK6; the disease is neoplasm.